

RevMan: review – intervention; 299208032716272921 (version 4.0)

Status: PUBLISHED VERSION

# Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures

Editors: Cochrane Epilepsy Group

Contact Person: Rebecca Bresnahan (rebecca.bresnahan@liverpool.ac.uk)

Department of Molecular and Clinical Pharmacology  
Institute of Translational Medicine, University of Liverpool  
Lower Lane  
Liverpool  
L9 7LJ  
UK

Rebecca Bresnahan [ <sup>1</sup> ] Mariangela Panebianco [ <sup>1</sup> ] Anthony G Marson [ <sup>1</sup> ] [ <sup>2</sup> ] [ <sup>3</sup> ]

[1] Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

[2] The Walton Centre NHS Foundation Trust, Liverpool, UK

[3] Liverpool Health Partners, Liverpool, UK

## Citation

Bresnahan R , Panebianco M , Marson AG . Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No.: [CD007783](#). DOI: [10.1002/14651858.CD007783.pub3](#).

## Dates

Version published: Issue 7, 2020 (01-07-2020)

Review first published: Issue 12, 2010

Protocol first published: Issue 2, 2009

## Abstract

### Background

This is an update of the Cochrane Review first published in 2010; it includes one additional study.

Primary generalised tonic-clonic seizures are a type of generalised seizure. Other types of seizures include: absence, myoclonic, and atonic seizures. Effective control of tonic-clonic seizures reduces the risk of injury and death, and improves quality of

life. While most people achieve seizure control with one antiepileptic drug, around 30% do not, and require a combination of antiepileptic drugs.

## Objectives

To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant primary generalised tonic-clonic seizures.

## Search methods

For the latest update, we searched these databases on 19 March 2019: Cochrane Register of Studies (CRS) Web, MEDLINE Ovid, and the [WHO International Clinical Trials Registry Platform \(ICTRP\)](#). The CRS includes records from the Cochrane Epilepsy Group Specialized Register, CENTRAL, Embase, and [ClinicalTrials.gov](#). We imposed no language restrictions. We also contacted GlaxoSmithKline, manufacturers of lamotrigine.

## Selection criteria

Randomised controlled parallel or cross-over trials of add-on lamotrigine for people of any age with drug-resistant primary generalised tonic-clonic seizures.

## Data collection and analysis

We followed standard Cochrane methodology; two review authors independently assessed trials for inclusion, evaluated risk of bias, extracted relevant data, and GRADE-assessed evidence. We investigated these outcomes: (1) 50% or greater reduction in primary generalised tonic-clonic seizure frequency; (2) seizure freedom; (3) treatment withdrawal; (4) adverse effects; (5) cognitive effects; and (6) quality of life. We used an intention-to-treat (ITT) population for all analyses, and presented results as risk ratios (RRs) with 95% confidence intervals (CIs); for adverse effects, we used 99% CIs to compensate for multiple hypothesis testing.

## Main results

We included three studies (total 300 participants): two parallel-group studies and one cross-over study. We assessed varied risks of bias across studies; most limitations arose from the poor reporting of methodological details. We meta-analysed data extracted from the two parallel-group studies, and conducted a narrative synthesis for data from the cross-over study.

Both parallel-group studies (270 participants) reported all dichotomous outcomes. Participants taking lamotrigine were almost twice as likely to attain a 50% or greater reduction in primary generalised tonic-clonic seizure frequency than those taking a placebo (RR 1.88, 95% CI 1.43 to 2.45; low-certainty evidence). The results between groups were inconclusive for the likelihood of seizure freedom (RR 1.55, 95% CI 0.89 to 2.72; very low-certainty evidence); treatment withdrawal (RR 1.20, 95% CI 0.72 to 1.99; very low-certainty evidence); and individual adverse effects: ataxia (RR 3.05, 99% CI 0.05 to 199.36); dizziness (RR 0.91, 99% CI 0.29 to 2.86; very low-certainty evidence); fatigue (RR 1.02, 99% CI 0.13 to 8.14; very low-certainty evidence); nausea (RR 1.60, 99% CI 0.48 to 5.32; very low-certainty evidence); and somnolence (RR 3.73, 99% CI 0.36 to 38.90; low-certainty evidence).

The cross-over trial (26 participants) reported that 7/14 participants with generalised tonic-clonic seizures experienced a 50% or greater reduction in seizure frequency with add-on lamotrigine compared to placebo. The authors reported four treatment withdrawals, but did not specify during which treatment allocation they occurred. Rash (seven lamotrigine participants; zero placebo participants) and fatigue (five

lamotrigine participants; zero placebo participants) were the most frequently reported adverse effects.

None of the included studies measured cognition. One parallel-group study (N = 153) evaluated quality of life. They reported inconclusive results for the overall quality of life score between groups (P = 0.74).

## Authors' conclusions

This review provides insufficient information to inform clinical practice.

Low-certainty evidence suggests that lamotrigine reduces the rate of generalised tonic-clonic seizures by 50% or more. Very low-certainty evidence found inconclusive results between groups for all other outcomes. Therefore, we are uncertain to very uncertain that the results reported are accurate, and suggest that the true effect could be grossly different.

More trials, recruiting larger populations, over longer periods, are necessary to determine lamotrigine's clinical use.

## Plain language summary

# Lamotrigine as add-on therapy for drug-resistant generalised tonic-clonic seizures

This is an update of a review first published in 2010.

## Background

Epilepsy is a common neurological (brain) condition that is characterised by repeated seizures. Most people can control their seizures with a single antiepileptic medicine, however, about 30% continue to have seizures. These people are said to have drug-resistant epilepsy. Lamotrigine is an antiepileptic medicine, which can be used as add-on treatment with other antiepileptic medication to try to manage drug-resistant epilepsy.

## Aim of review

This review studied whether lamotrigine was effective and tolerable when used as add-on treatment, alongside other antiepileptic medicines, for people with drug-resistant generalised epilepsy (affecting the entire brain from onset) with tonic clonic-seizures (seizures where people lose consciousness and jerk quickly and rhythmically).

## Results

We found three trials, involving 300 people, that investigated lamotrigine for people with drug-resistant generalised tonic-clonic seizures. People who received add-on lamotrigine were almost twice as likely to have a 50% or greater reduction in the number of generalised tonic-clonic seizures than people who received add-on placebo (an inactive, dummy drug). Lamotrigine did not significantly affect: the number of people who were completely free of seizures, the number of people who withdrew from treatment, or the number of people who experienced common adverse effects.

However, we are very uncertain whether these findings are accurate. This is because there were not many people involved in the studies, and we are unclear about the methods some of the studies used. For this reason, we cannot comment on the use of lamotrigine.

More trials, which include more people, and are carried out over longer time periods are needed to properly guide the use of lamotrigine for people with drug-resistant generalised tonic-clonic seizures.

The evidence is current to March 2019.

## Summary of findings

### Summary of findings 1

### Add-on lamotrigine compared to placebo for drug-resistant generalised tonic-clonic seizures

#### Add-on lamotrigine compared to placebo for drug-resistant generalised tonic-clonic seizures

**Patient or population:** people with drug-resistant generalised tonic-clonic seizures

**Setting:** outpatient

**Intervention:** add-on lamotrigine

**Comparison:** add-on placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with placebo	Risk with lamotrigine				
<b>50% or greater reduction in seizure frequency</b> Follow-up (range): 19 to 24 weeks	<b>Study population</b>		<b>RR 1.88</b> (1.43 to 2.45)	<b>270</b> (2 RCTs)	⊕⊕⊕⊖ Low <sup>a,b</sup>	The outcome was reported by a cross-over study but the data could not be incorporated into the meta-analysis.  In the cross-over study, 7/17 participants with tonic-clonic seizures experienced a 50% or greater seizure reduction with add-on lamotrigine compared to add-on placebo. Only 1/17 participants had an increased seizure frequency with add-on lamotrigine compared to placebo. Of importance, seizure frequency was compared between the treatment arms and not to the baseline period.
	338 per 1000	636 per 1000 (484 to 829)				
<b>Seizure freedom (i.e. total cessation of seizure activity)</b> Follow-up (range): 19 to 24 weeks	<b>Study population</b>		<b>RR 1.55</b> (0.89 to 2.72)	<b>270</b> (2 RCTs)	⊕⊕⊕⊖ Very low <sup>a,c</sup>	
	125 per 1000	194 per 1000 (111 to 340)				
<b>Treatment withdrawal</b>	<b>Study population</b>		<b>RR 1.20</b> (0.72 to	<b>270</b> (2 RCTs)	⊕⊕⊕⊖ Very	The outcome was reported by a cross-

Follow-up (range): 19 to 24 weeks		162 per 1000	194 per 1000 (116 to 322)	1.99)		low <sup>a,c</sup>	over study but the data could not be incorporated into the meta-analysis.  Four of 26 participants in the cross-over study withdrew from treatment. Two withdrew from lamotrigine due to rash, one withdrew during their first treatment arm, another was ineligible for inclusion, We do not know whether the participants had tonic-clonic seizures or which treatment the latter two were receiving at the time of withdrawal..
Adverse effects  Follow-up (range): 19 to 24 weeks	Dizziness	Study population		RR 0.91 (0.29 to 2.86)	270 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>a,c</sup>	The outcome was reported by a cross-over study but the data could not be incorporated into the meta-analysis.  2/26 participants in the cross-over study experienced dizziness, however, we do not know whether the participants had tonic-clonic seizures. No participants reported dizziness whilst receiving placebo.
		74 per 1000	67 per 1000 (21 to 210)				
	Fatigue	Study population		RR 1.02 (0.13 to 8.14)	270 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>a,c</sup>	
		22 per 1000	23 per 1000 (3 to 180)				
	Nausea	Study population		RR 1.60 (0.48 to 5.32)	270 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>a,c</sup>	
		51 per 1000	82 per 1000 (25 to 274)				
	Somnolence	Study population		RR 3.73 (0.36 to 38.90)	270 (2 RCTs)	⊕⊕⊕⊕ Very low <sup>a,c</sup>	The outcome was reported by a cross-over study but the data could not be incorporated into the meta-analysis.  2/26 participants in the cross-over study experienced somnolence, however, we do not know whether the participants had tonic-clonic seizures. No participants reported somnolence whilst receiving placebo.
		7 per 1000	27 per 1000 (3 to 286)				
<p><b>*The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).</p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio;</p>							

**GRADE Working Group grades of evidence**

**High certainty.** We are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty.** We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty.** Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty.** We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

<sup>a</sup> Evidence downgraded once for risk of bias. The two studies included in the meta-analysis failed to clarify whether outcome assessors were blinded. One study also failed to declare the treatment allocation of all randomised participants who withdrew from treatment. Therefore, we awarded unclear risk of bias.

<sup>b</sup> Evidence downgraded once for imprecision. The number of events did not satisfy the optimal information size (< 400 events).

<sup>c</sup> Evidence downgraded twice for imprecision. The number of events did not satisfy the optimal information size (< 100 events).

## Background

This is an update of a Cochrane Review first published in 2010 ([Tjia-Leong 2010](#)); it includes one additional study.

Epilepsy is defined as the occurrence of repeated epileptic seizures. It is a common neurological disorder, with an estimated cumulative incidence of 68 per 100,000 people per year ([Fiest 2017](#)), and a worldwide prevalence of four to 10 per 1000 people ([WHO 2019](#)). Although the majority of people with epilepsy are able to achieve control of their seizures by using adequate doses of conventional antiepileptic drugs (AEDs), up to 30% of people develop drug-resistant epilepsy (i.e. drug resistance), and continue to have seizures ([Cockerell 1995](#)). The internationally accepted definition of drug-resistant epilepsy is the failure to respond to adequate trials of two tolerated, appropriately chosen, and compliantly used antiepileptic drug regimens, given with the intention of achieving complete cessation of seizures. The two antiepileptic drugs can be used independently, or in combination ([Kwan 2010](#)). For the purposes of this review, we applied this definition when assessing the eligibility of studies for inclusion.

## Description of the condition

Around 30% to 40% of people have seizures that are generalised at onset; most of them are thought to have a genetic predisposition, and have primary generalised (idiopathic) epilepsy ([Bancaud 1989](#)). Generalised seizures are those in which the first clinical and electroencephalographic changes indicate that large parts of both hemispheres of the brain are involved at the onset of the seizure. There is nearly always impaired consciousness. The common subtypes of generalised seizures are tonic-clonic seizures (grand mal), absence seizures (petit mal), and myoclonic seizures. Such seizures tend to present in childhood and adolescence; common syndromes include childhood absence, juvenile absence, juvenile myoclonic, and generalised epilepsy with tonic-clonic seizures on waking. Around 20% to 30% of people with generalised onset seizures fail to achieve seizure control on monotherapy, and often require a combination of drugs to maximise seizure control ([Cockerell 1995](#)).

## Description of the intervention

In an attempt to achieve seizure control, clinicians often prescribe multiple AEDs. Lamotrigine, the focus of this review, is an antiepileptic drug that can be used as an add-on for people with drug-resistant epilepsy. It was initially licensed for people with



drug-resistant focal epilepsy, with few studies examining its effect in people with drug-resistant generalised seizures. In the UK, it has been licensed for generalised tonic-clonic seizures as monotherapy and as add-on therapy. Numerous short-term, randomised, double-blinded, placebo-controlled studies, predominantly of cross-over designs, have confirmed the efficacy of lamotrigine, when used as add-on therapy for people with drug-resistant, focal epilepsy ([Ramaratnam 2016](#)).

## How the intervention might work

Lamotrigine acts by blocking voltage-gated sodium channels to stabilise the pre-synaptic neuronal membrane ([Leach 1995](#)). There is some evidence that lamotrigine also selectively inhibits the production of excitatory neurotransmitters, such as glutamate and aspartate ([Deng 2013](#)). Its full mechanism of action remains unknown.

Although serum concentrations of lamotrigine are not thought to be influenced by interactions with most drugs, they are affected by interactions with other anti-epileptic drugs. Specifically, drug levels of lamotrigine are markedly increased by an interaction with valproate, which inhibits glucuronidation, the main metabolic pathway of lamotrigine ([Rowland 2006](#); [Weintraub 2005](#)). Levels are decreased in the presence of enzyme-inducing drugs, such as phenytoin, carbamazepine, and oxcarbazepine ([Weintraub 2005](#)). A pharmacodynamic interaction is common when lamotrigine is co-prescribed with carbamazepine, and the symptoms of neurotoxicity (i.e. headache, nausea, dizziness, diplopia, and ataxia) can be avoided by reducing the dose of carbamazepine ([Besag 1998](#)).

Adverse effects of lamotrigine include skin rash, dizziness, nausea, diplopia, and ataxia. Increased toxicity and paradoxical deterioration of seizure control may occur when lamotrigine is used in combination with other AEDs.

## Why it is important to do this review

Lamotrigine may be efficacious as an add-on for generalised tonic-clonic seizures ([Beran 1998](#)). However, compared with focal epilepsies, evidence for the effectiveness of lamotrigine for people with generalised epilepsy syndromes is limited ([Marson 2007](#)). This review evaluated whether the currently available literature can adequately determine the efficacy of lamotrigine in people with primary generalised epilepsy. This review does not address the effects of lamotrigine for Lennox-Gastaut syndrome or for absence seizures, as both have already been discussed elsewhere ([Hancock 2013](#); [Brigo 2019](#)).

## Objectives

To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant primary generalised tonic-clonic seizures.

## Methods

### Criteria for considering studies for this review

#### Types of studies

We only included trials that met all of the following criteria:

1. randomised and controlled, with an adequate method of concealment of randomisation;
2. double-blind, single-blind, or unblinded;

3. placebo- or actively-controlled;
4. parallel-group or cross-over design.

## Types of participants

Participants of any age, with drug-resistant, primary generalised epilepsy (i.e. experiencing myoclonic epilepsy, generalised epilepsy with tonic-clonic seizures on awakening, and other idiopathic seizures). We excluded studies involving participants with absence epilepsy and Lennox Gastaut syndrome.

## Types of interventions

1. The active treatment group received treatment with lamotrigine in addition to their conventional antiepileptic drug (AED) treatment.
2. The control group received a matched placebo or an active comparator, such as an alternative AED, in addition to their conventional AED treatment.

## Types of outcome measures

### Primary outcomes

1. **50% or greater reduction in primary generalised tonic-clonic seizure frequency:** the proportion of individuals with a 50% or greater reduction in seizure frequency during the treatment period compared to the pre-randomizations baseline period. We chose this because it is commonly reported in this type of study, and can be calculated for studies that do not report this outcome, provided that baseline seizure data were recorded.

### Secondary outcomes

1. **Seizure freedom:** the proportion of individuals with a 100% reduction in primary generalised tonic-clonic seizure frequency (complete cessation seizures) during the treatment period (including maintenance phase) compared to the pre-randomizations baseline period.
2. **Treatment withdrawal.** We used the proportion of individuals having treatment withdrawn during the course of a treatment period as a measure of global effectiveness. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy, or a combination. However, in trials of a relatively short duration, adverse effects are likely to be the main reason for treatment withdrawal.
3. **Adverse effects:**
  - a. The proportion of individuals experiencing any of the following five adverse effects (we chose these adverse effects because we considered them to be important and common adverse effects of AEDs:
    - i. ataxia;
    - ii. dizziness;
    - iii. fatigue;
    - iv. nausea;
    - v. somnolence.
  - b. The proportion of individuals experiencing the five most common adverse effects, if different from those listed above.
4. **Cognitive effects.** At present, there is no consensus as to which instrument should be used to assess the effects of AEDs on cognition. In view of this difficulty, we planned to tabulate results where a specific instrument was used



to assess the effects of lamotrigine on cognition, but we did not combine the results in a meta-analysis.

5. **Quality of life.** There is no consensus on which instruments should be used to assess quality of life, so we tabulated the results rather than combine them in a meta-analysis.

## Search methods for identification of studies

### Electronic searches

We ran searches for the original review in June 2010. We ran subsequent searches in July 2012, October 2013, February 2014, February 2017, and March 2019. For the latest update, we searched the following databases on 19 March 2019:

1. Cochrane Register of Studies Web (CRS Web), using the search strategy shown in [Appendix 1](#);
2. Medline Ovid (1946 to 19 March 2019), using the search strategy shown in [Appendix 2](#);
3. [WHO International Clinical Trials Registry Platform \(ICTRP\)](#), using the search strategy shown in [Appendix 3](#).

The Cochrane Register of Studies includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised or quasi-randomised, controlled trials from Embase, and [ClinicalTrials.gov](#).

### Searching other resources

In addition, we contacted the manufacturers of lamotrigine, and checked any cross-references from identified publications.

## Data collection and analysis

### Selection of studies

Two review authors (RB and MP) independently assessed the records identified by both the electronic searches and handsearches for their eligibility for this review. First, we (the two review authors), screened the titles and abstracts of all the identified records. At this stage, we eliminated any records that were duplicates, or that did not meet the predefined inclusion criteria. We retrieved the full-text publications for the remaining, potentially eligible records, and completed a more in-depth screening. We resolved any disagreements by discussion. If disagreements persisted, the third author (AGM) arbitrated.

### Data extraction and management

We extracted the following data from the studies that met our inclusion criteria:

1. Methodological or trial design:
  - a. method of randomizations and allocation concealment;
  - b. method of blinding;
  - c. whether any participants had been excluded from reported analyses;
  - d. duration of baseline period;
  - e. duration of treatment period;
  - f. dose(s) of lamotrigine tested.

## 2. Participant and demographic information:

- a. total number of participants allocated to each treatment group;
- b. age and sex;
- c. seizure types;
- d. number and description of background drugs;
- e. number of seizures prior to randomisation.

## 3. Treatment data:

- a. medication dose per treatment group;
- b. route of administration for treatment.

## 4. Follow-up data:

- a. the number of participants in each group achieving 50% or greater reduction in seizures;
- b. the number of participants in each group achieving total cessation of seizures;
- c. the number of participants in each group who had treatment withdrawn, and reasons for treatment withdrawal;
- d. for those excluded; the reason for exclusion, whether any of those excluded completed the treatment phase.

## Assessment of risk of bias in included studies

Two review authors (RB and MP) independently assessed the risk of bias associated with the included studies, using the Cochrane 'Risk of bias' tool, as outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#)). The Cochrane 'Risk of bias' tool comprises seven specific domains:

- 1. random sequence generation;
- 2. allocation concealment;
- 3. blinding of participants and personnel;
- 4. blinding of outcome assessors;
- 5. incomplete outcome data;
- 6. selective outcome reporting;
- 7. other bias.

For each entry, the two review authors made a judgement (low risk of bias, high risk of bias, or unclear risk of bias) and provided support for the decision by an agreed review author comment, or by a quote taken directly from the corresponding trial publication.

When judging overall risk of bias associated with each study, we followed the guidance suggested by [Higgins 2017](#). Specifically, if a study was awarded low risk of bias across all domains, we considered the study to be at low risk of bias overall. If we judged that a study was at unclear risk of bias for one or more domains, then we would award it unclear risk of bias overall. Likewise, if we judged that a study was at high risk of bias for one or more domain, then we would consider the study to be at high risk of overall bias.

## Measures of treatment effect

We recorded the number of participants per randomised group who experienced each outcome. We analysed data according to the intention-to-treat principle,

whereby we assumed that participants who did not complete follow-up, or who provided insufficient seizure data, were non-responders. To analyse dichotomous outcomes (50% or greater reduction in seizure frequency, seizure freedom, treatment withdrawal, and adverse effects), we calculated risk ratios (RRs) with 95% confidence intervals (CIs), using the Mantel–Haenszel method. However, for individual adverse effects, we quoted 99% CIs, to make allowance for multiple testing.

Due to the lack of agreement and consistency about how cognitive effects and quality of life should be measured, we tabulated any available results and conducted a narrative synthesis.

## Unit of analysis issues

For cross-over studies, we had planned to extract data from the first treatment period, and incorporate the data into the meta-analysis, as if the data had been derived from a parallel-group design study. This would prevent data gathered from the same participant from contributing to both the intervention and control treatment groups, thus avoiding any unit of analysis issues.

## Dealing with missing data

Where outcomes of interest were not reported, we contacted the original authors and study sponsors for further information.

## Assessment of heterogeneity

We assessed clinical heterogeneity by comparing the characteristics of the participants recruited into the included studies, including factors, such as age and sex. We assessed methodological heterogeneity by comparing the study design of the individual studies, including: method of randomisation, allocation concealment and blinding, and duration of treatment. We assessed statistical heterogeneity using the  $I^2$  statistic. An  $I^2$  value  $< 40\%$  suggested that heterogeneity might not be important,  $40\%$  to  $60\%$  equated moderate heterogeneity, and  $50\%$  to  $90\%$  implied substantial heterogeneity.

## Assessment of reporting biases

We requested trial protocols to determine the predefined outcomes of the studies. In instances where we were unable to get the trial protocol, we compared the outcomes listed in the methods section to those reported in the results section of the text. We reported any inconsistencies in the 'Risk of bias' table.

Due to the limited number of included studies, we were unable to develop a funnel plot to evaluate reporting bias.

## Data synthesis

We analysed all data using Review Manager 5 ([Review Manager 2014](#)). Where the  $I^2$  statistic indicated that heterogeneity was likely unimportant ( $I^2 < 40\%$ ), we summarised results using a fixed-effect model. When the  $I^2$  statistic indicated either moderate or substantial heterogeneity ( $I^2 \geq 40\%$ ), or we detected clinical heterogeneity despite insignificant statistical heterogeneity, we used a random-effects model for the meta-analysis.

## Subgroup analysis and investigation of heterogeneity

Due to the small number of included studies, we were unable to conduct any meaningful subgroup analysis. If it had been possible, we would have undertaken a subgroup analysis according to age groups (children versus adults), seizure type, and baseline severity.

## Sensitivity analysis

We had also planned to complete a sensitivity analysis to test the robustness of the meta-analysis. Specifically, we would have excluded studies from the meta-analysis that were at high-risk of bias, to determine the impact on the overall effect size estimated.

## Summary of findings and assessment of the certainty of the evidence

We used the GRADE approach to summarise findings, as detailed in the GRADE handbook ([Schünemann 2013](#)). We imported data into [GRADEpro GDT](#) software from Review Manager 5 software to create a 'Summary of findings' table ([GRADEpro GDT](#); [Review Manager 2014](#)). We assessed the certainty of the evidence for the following outcomes in the 'Summary of findings' table: 50% or greater reduction in seizure frequency, seizure freedom, treatment withdrawal, and the adverse effects of dizziness, fatigue, nausea, and somnolence.

We chose to include 50% or greater reduction in seizure frequency and seizure freedom as these were the only two efficacy outcomes included in the review. We also chose to include treatment withdrawal as this is a measure of global effectiveness that encompasses both efficacy and tolerability. Finally, we wanted to include all five adverse effects that are considered to be important and common with AEDs (ataxia, dizziness, fatigue, nausea and somnolence). However, because we were limited by the number of outcomes that can be GRADE-assessed and included in the summary of findings table, we decided to exclude ataxia as our previous knowledge of the evidence base suggested that ataxia would not be highly reported. We therefore prioritised the GRADE-assessment of the other four adverse effects.

# Results

## Description of studies

### Results of the search

During the original search, conducted in June 2010, we identified five randomised controlled studies investigating the use of add-on lamotrigine in participants with drug-resistant generalised epilepsy ([Beran 1998](#); [Biton 2005](#); [Eriksson 1998](#); [Motte 1997](#); [Sander 1990](#)). Of the studies identified during the original searches, only two of the studies fulfilled the protocol criteria for inclusion, one cross-over and one parallel study ([Beran 1998](#); [Biton 2005](#)).

The electronic searches conducted between July 2012 and March 2019, identified a total of 454 records that were potentially eligible for inclusion ([Figure 1](#)). We also identified five records through handsearching. We automatically removed 115 records, as they were duplicates. Next, we removed another 240 records, because they were obviously irrelevant. We screened the titles and abstracts of the remaining 104 records, and determined that only eight of the identified records, which related to four individual studies, were potentially eligible for inclusion. We retrieved and screened the full-text publications of the remaining eight records, five of which we found to be eligible for inclusion. Four related to [Biton 2010](#), and two were additional references for [Biton 2005](#). We excluded two of the full-texts ([Brzakovic 2012](#); [Chung 2009](#)).

In total, we assessed that 10 records, relating to three individual studies, were eligible ([Beran 1998](#); [Biton 2005](#); [Biton 2010](#)). We excluded five records, relating to five individual studies ([Brzakovic 2012](#); [Chung 2009](#); [Eriksson 1998](#); [Motte 1997](#); [Sander 1990](#)).

## Included studies

We included three studies in this update ([Beran 1998](#); [Biton 2005](#); [Biton 2010](#)). We summarised the relevant information for each study in the 'Characteristics of included studies' tables.

## Study design

One study was a cross-over study ([Beran 1998](#)) whilst two studies were parallel-group studies ([Biton 2005](#); [Biton 2010](#)).

The cross-over study ([Beran 1998](#)) featured an eight week baseline period, followed by two eight week treatment periods, separated by a four week washout period. No detailed data were provided for either phase of the cross-over study.

The parallel-group studies ([Biton 2005](#); [Biton 2010](#)) both used the same study duration for adolescent and adult participants; a two-week screening period, an eight-week baseline period, and a 19-week treatment period (7-week dose-escalation plus a 12-week maintenance period). [Biton 2005](#), however, also included children (aged 2 to 12 years) and for these participants the dose-escalation was 12-weeks, leading to an overall treatment period of 24-weeks, opposed to 19-weeks for adults. All other phases remained the same in duration.

## Participants

[Beran 1998](#) included a small sample of 26 participants, aged between 15 and 50 years (mean 29 years), with drug-resistant generalised epilepsy. Of the 26 participants, 17 participants had generalised epilepsy with tonic-clonic seizures (12 with tonic-clonic and absence seizures, two with tonic-clonic seizures only, one with tonic-clonic and myoclonic seizures, two with tonic-clonic, absence and myoclonic seizures). Only the 17 participants with tonic-clonic seizures were included in our intention-to-treat analysis.

Similar to [Beran 1998](#), [Biton 2010](#) included both adolescents and adults, but not children. Specifically, [Biton 2010](#) involved 153 randomised participants (76 lamotrigine, 77 placebo), aged 13 years and over. In contrast, [Biton 2005](#) included children, as well as adults and adolescents. [Biton 2005](#) included 121 randomised subjects, aged 2 to 55 years (mean 26 years).

Notably, four of the participants from [Biton 2005](#) did not receive any study medication and it was not clear to which group they had been randomised. As a result, we were only able to include 117 participants (58 lamotrigine, 59 placebo) in our intention-to-treat analysis includes.

For both [Biton 2005](#) and [Biton 2010](#), participants had been receiving 1 or 2 established AEDs for at least four weeks prior to screening. In contrast, [Beran 1998](#) included participant who had previously been treated with up to four established antiepileptic drugs (AEDs). For all three studies, participants had to have drug-resistant seizures despite therapy with a stable AED regimen of at least one or more other AEDs, appropriate for the type of epilepsy when given in adequate doses.

The exclusion criteria for all three studies were similar. They excluded people with: a history of focal seizures, interictal expression of focal seizures revealed by EEG, Lennox-Gastaut syndrome, confounding organic or psychiatric problems, progressive neurological disease, associated systemic disease, chronic medication that might influence seizure control, recent use of any investigational AED, previous exposure to lamotrigine, and abuse of alcohol, other prescription or non-prescription drugs. Furthermore, the three studies each excluded women who were pregnant or at risk of pregnancy, and women who were breastfeeding.

## Interventions



Participants were not randomised to a single dose in any of the studies but took a range of doses, depending on clinical response, age group, and the concurrent administration of other antiepileptic drugs (AEDs).

Valproate was the most common concomitant AED. Lamotrigine was administered at lower doses when used with an enzyme inhibitor like valproate (75 mg to 250 mg daily). Conversely, higher doses were administered when used with other enzyme inducing AEDs (150 mg to 500 mg daily). Additionally, for [Biton 2010](#), participants who were taking an AED other than valproate and taking multiple enzyme-inducing AEDs were titrated to 300 mg/day. Conversely, participants under the age of 12 years (N = 23) had a dosing range between 2.25 mg and 7.5 mg/kg/day ([Biton 2005](#)).

## Excluded studies

We excluded five studies from this review update ([Brzakovic 2012](#); [Chung 2009](#); [Eriksson 1998](#); [Motte 1997](#); [Sander 1990](#)). We summarised the reasons for exclusion in the 'Characteristics of excluded studies' tables.

Four of the studies featured ineligible study populations ([Chung 2009](#); [Eriksson 1998](#); [Motte 1997](#); [Sander 1990](#)). Two studies included participants with a diagnosis of Lennox-Gastaut syndrome ([Eriksson 1998](#); [Motte 1997](#)); one study included participants with a diagnosis of focal, rather than generalised epilepsy ([Chung 2009](#)); the majority of participants in one study had drug-resistant focal seizures, and although three of the participants did have primary generalised tonic-clonic seizures, data were not stratified according to seizure subtype or order of treatment ([Sander 1990](#)). One study was not a randomised controlled trial ([Brzakovic 2012](#)).

## Risk of bias in included studies

Summaries of our judgements for each risk of bias domain, across the included studies, are presented in [Figure 2](#) and [Figure 3](#). Reasons supporting our judgements, including quotations taken directly from the text publications and specific review author comments, can be found in the 'Risk of bias' tables.

### Allocation

One study failed to explicitly state how the randomisation sequence was generated or how allocation was concealed, therefore, we assessed it as an unclear risk of bias ([Beran 1998](#)). The other two studies specified that the randomisation schedule was computer-generated by the study sponsor, GlaxioSmithKline; they used central randomisation and an interactive voice response system to allocate participants to treatment groups, therefore, we assessed them at a low risk of bias.

### Blinding

All three studies reported they were double-blinded. However, one study did not provide a description of the blinding process, and we assessed it as unclear risk of performance and detection bias ([Beran 1998](#)). The other two studies specified that matching placebo tablets were used, consequently, we judged them at low risk of performance bias. Since they did not specify whether outcome assessors were blinded, we assessed that the studies were at unclear risk of detection bias.

### Incomplete outcome data

All three studies reported losses to follow-up and treatment withdrawals.

[Beran 1998](#) reported that 4/26 participants withdrew from the trial before completion, but did not specify which treatment group the participants were randomised to at the time of withdrawal, as a result, we judged the study at high risk of attrition bias.



[Biton 2005](#) reported that 16/58 lamotrigine-randomised participants and 14/59 placebo-randomised participants withdrew from the trial prior to completion. Data from the 30 participants who withdrew from treatment, but who all received at least one dose of the study drug, were incorporated into the efficacy analysis by using an intention-to-treat analysis. An additional 4/117 participants did not receive at least one dose of the study drug, but their treatment group was not specified, so were not included in the meta-analysis; for this reason, we assessed that the study was at unclear risk of attrition bias.

[Biton 2010](#) reported that 10/76 lamotrigine-randomised participants and 8/77 placebo-randomised participants withdrew from the study prior to completion, but they used an intent-to-treat analysis. Therefore, we assessed the study had a low risk of attrition bias.

## Selective reporting

We were unable to attain a trial protocol for one study, but the outcomes defined in the methods section of the full-text publication were fully reported in the results section. We obtained the summary of the trial protocol for the remaining two studies, which fully reported all predefined outcomes. Therefore, we assessed all three studies at low risk of reporting bias.

## Other potential sources of bias

[Beran 1998](#) experienced difficulties when recording participants' daily seizure frequency. Specifically, 22 of the randomised participants experienced absence seizures. This seizure type can be difficult to accurately record. The authors, therefore, only collected seizure frequency data on days when they were sure that a complete and accurate seizure record had been kept. The mean monthly seizure rate was then calculated based from the number of days were a complete seizure record was available. It is thus possible that the mean monthly seizure frequency calculated could be considerably different from the true monthly seizure frequency. This would be especially problematic if the number of generalised tonic-clonic seizures correlated with the number of absence seizures, in any way. We thus assessed that the study by [Beran 1998](#) was at unclear risk of other bias.

## Effects of interventions

We did not conduct a meta-analysis in the previous version of this review as we included two studies that were too heterogeneous. Specifically, the two studies varied in: study design (one study was a parallel-group trial ([Biton 2005](#)) whereas the other was a cross-over trial ([Beran 1998](#))), treatment doses used (200 mg to 400 mg/day versus 75 mg to 150 mg/day), and length of follow-up (19 weeks to 24 weeks versus 8 weeks).

During this review update, we identified a second parallel group study ([Biton 2010](#)) with the same duration of treatment as the previously included parallel-group study ([Biton 2005](#)). We therefore decided to conduct a meta-analysis of the two parallel-group studies, whilst continuing to describe the results from the cross-over study narratively ([Beran 1998](#)). Importantly, the narrative synthesis considers data collected from the same participant for both the intervention (lamotrigine) and control (placebo) treatment periods, due to the cross-over design of the study. Unfortunately, the information regarding only the first treatment period was not available.

The results can be found summarised in the [Summary of findings table 1](#).

## Primary outcome

### 50% or greater reduction in primary generalised tonic-clonic seizure frequency

All three studies reported this outcome, however, we only used data extracted from the two parallel-group studies for the meta-analysis (Biton 2005; Biton 2010). We calculated that participants receiving add-on lamotrigine were nearly twice as likely to attain a 50% or greater reduction in primary generalised tonic-clonic seizure frequency, compared to participants who received add-on placebo (risk ratio (RR) 1.88, 95% confidence interval (CI) 1.43 to 2.45;  $P < 0.001$ ; 2 studies; 270 participants; Analysis 1.1).

Beran 1998 (N = 17) reported that seven participants with tonic-clonic seizures experienced a 50% or greater reduction in primary generalised tonic-clonic seizure frequency with add-on lamotrigine compared to with add-on placebo. Importantly, seizure frequency was compared between the two treatment arms to calculate the percentage change rather than to the pre-randomisation baseline period. Analysis using the non-parametric Mann Whitney U test revealed a significant reduction in seizure frequency with add-on lamotrigine compared with add-on placebo ( $P = 0.03$ ). Only one participant experienced an increase in seizure frequency when receiving add-on lamotrigine compared to when receiving add-on placebo.

## Secondary outcomes

### 1. Seizure freedom

The two parallel-group studies (Biton 2005; Biton 2010), presented data for the outcome, seizure freedom, however, the cross-over study by Beran 1998 did not.

We calculated that a greater proportion of participants attained seizure freedom from primary generalised tonic-clonic seizures when receiving add-on lamotrigine compared to when receiving add-on placebo. The meta-analysis (Analysis 1.2), however, indicated that the results were inconclusive and we were unable to determine whether there was an effect of vigabatrin for seizure freedom (RR 1.55, 95% CI 0.89 to 2.72;  $P = 0.12$ ; 2 studies; 270 participants).

### 2. Treatment withdrawal

All three studies measured treatment withdrawal. For the parallel group studies, the results were inconclusive (RR 1.20, 95% CI 0.72 to 1.99;  $P = 0.48$ ; 2 studies; 270 participants; Analysis 1.3). For participants randomised to placebo, the most common reason for treatment withdrawal was non-compliance (total 10/22 withdrawals). For participants randomised to lamotrigine groups, the most common reason for treatment withdrawal varied between the two studies. Non-compliance remained the most common reason for treatment withdrawal in Biton 2010 (7/10 withdrawals); whereas loss to follow-up and adverse effects were the most common reasons in Biton 2005 (5/16 withdrawals). Other reasons for treatment withdrawal for both treatment groups included withdrawal of consent and lack of efficacy.

Beran 1998 reported that four of the total 26 randomised participants withdrew from treatment. Two participants withdrew from the lamotrigine group due to rash, one participant withdrew during the first treatment phase, and the other participant was later found to be ineligible. There was no information on treatment group for the latter two treatment withdrawals and we do not know the seizure type of the four participants who withdrew.

### 3. Adverse effects

#### a. The proportion of individuals experiencing any of the following five listed adverse effects

Both parallel-group studies reported all five adverse effects. The results were inconclusive for all adverse effects (2 studies, 270 participants; Analysis 1.4):

1. Ataxia – RR 3.05, 99% CI 0.05 to 199.36;  $P = 0.49$ ;
2. Dizziness – RR 0.91, 99% CI 0.29 to 2.86;  $P = 0.84$ ;

3. Fatigue – RR 1.02, 99% CI 0.13 to 8.14; P = 0.99;
4. Nausea – RR 1.60, 99% CI 0.48 to 5.32; P = 0.32;
5. Somnolence – RR 3.73, 99% CI 0.36 to 38.90; P = 0.15.

[Beran 1998](#) reported that 3/26 (12%) of the participants experienced ataxia, 2/26 (8%) experienced dizziness, and 2/26 (8%) experienced somnolence, whilst receiving lamotrigine. None of the participants in the placebo group reported any of these symptoms. The report described tiredness rather than fatigue; 1/26 (4%) participants reporting tiredness in the lamotrigine group, 5/26 (19%) reported it in the placebo group. Of significance, the report only listed adverse effects that were reported by more than two participants. Although nausea was not listed amongst the adverse effects, it is possible that two or fewer participants reported it.

#### **b. The proportion of individuals experiencing the five most common adverse effects, if different from those listed above**

Both parallel studies reported headache as the most common adverse effect during the studies; there were more reports of headache in the placebo group, but the results were inconclusive (RR 0.75, 99% CI 0.38 to 1.50; P = 0.29; 2 studies, 270 participants; [Analysis 1.4](#)).

[Biton 2010](#) reported that vomiting was the second most commonly reported adverse effect, [Biton 2005](#) reported it was the fifth most commonly reported; the results were inconclusive (RR 1.27, 99% CI 0.39 to 4.15; P = 0.60; 2 studies, 270 participants; [Analysis 1.4](#)).

Convulsion was the fourth most commonly reported adverse effect in [Biton 2005](#); while more common in the placebo group, the results were inconclusive (RR 0.34, 99% CI 0.05 to 2.13; P = 0.13; 2 studies, 270 participants; [Analysis 1.4](#)).

Pyrexia was the fifth most commonly reported adverse effect in [Biton 2010](#); the results were inconclusive (RR 0.87, 99% CI 0.21 to 3.52; P = 0.80; 2 studies, 270 participants; [Analysis 1.4](#)).

In addition to the adverse effects listed above, [Beran 1998](#) also reported rash, headache, accidental injury, ataxia, diplopia, and tremor in their top five reported adverse effects. Rash was the most commonly reported adverse effect (lamotrigine = 7/26 (27%); placebo = none); headache and accidental injury were tied for the third most common, with 2/26 reported in each group; ataxia, diplopia, and tremor were tied for the fourth most common (lamotrigine = 3/26 (12%) reported ataxia and diplopia; placebo = none; lamotrigine = 2/26 (8%) reported tremor; placebo = 1/26 (4%)).

## **4. Cognitive effects and quality of life**

None of the three included studies assessed any measures of cognitive effect.

## **5. Quality of life**

Only one study (N = 153 participants) assessed quality of life with the Quality of Life in Epilepsy-31-P (QOLIE-31P) questionnaire. The mean overall quality of life score for both treatment groups increased from baseline to the end of treatment, but the results were inconclusive (P = 0.74; [Table 1](#); [Biton 2010](#)).

# **Discussion**

## **Summary of main results**

We found three short-term randomised controlled trials that met our inclusion criteria, two of which were parallel-group studies ([Biton 2005](#); [Biton 2010](#)), and one of which

was a cross-over study ([Beran 1998](#)). We combined the results from the two parallel-group studies in a meta-analysis, and described the results from the cross-over study narratively.

Low-certainty evidence suggested that add-on lamotrigine almost doubled the likelihood that people with generalised tonic-clonic seizures would attain a 50% or greater reduction in the frequency of their seizures, compared to add-on placebo. Very low-certainty evidence suggested inconclusive results for the likelihood of seizure freedom between add-on lamotrigine and placebo. Very low-certainty evidence suggested inconclusive results for the likelihood of adverse events, such as treatment withdrawal and individual adverse effects.

Importantly, the low- to very low-certainty evidence for all outcomes means that we are uncertain to very uncertain that the effect sizes that we reported are accurate. It is possible that the true effect could be considerably different to that estimated, both in terms of magnitude and direction. The uncertainty of the results may reflect the very low number of studies and participants that contributed data to the meta-analysis.

## Overall completeness and applicability of evidence

The most notable limitation of this review is the lack of studies that were eligible for inclusion. We included three studies, however, only data from two of the studies were suitable for meta-analysis. Even after combining the two study populations, the total sample size remained relatively small (270 participants in total). Less frequent events, such as seizure freedom and the incidence of individual adverse effects, require larger sample sizes to detect a significant therapeutic effect ([Hajian-Tillaki 2011](#)). From this viewpoint, it is possible that add-on lamotrigine might have a therapeutic effect on these outcomes that we have currently been unable to detect.

The limited data also prevented us from performing subgroup analyses. We had originally planned to conduct subgroup analyses according to the age of participants, their seizure type, and their baseline seizure frequency. However, splitting the small sample size further would have rendered the results of any subgroup analysis meaningless, and increased the likelihood of a type II error occurring.

The studies did not report all of the review outcomes; for example, [Beran 1998](#) did not report seizure freedom, and none of the included studies reported any measures of cognitive effect. Only [Biton 2010](#) measured and reported changes in quality of life. This also impacted the completeness and certainty of the evidence.

The design of the included studies also affected the applicability of the evidence. All three included studies were of short duration; hence, longer term outcomes were not assessed. Long-term outcomes are especially important in chronic conditions, such as epilepsy, where the medications could potentially be taken over a lifetime.

All three studies tried to account for interactions between lamotrigine and enzyme-inhibiting drugs (valproate) and enzyme-inducing drugs (e.g. carbamazepine) by altering initial lamotrigine doses to compensate. Of note, the initial target doses were different between the studies. For example, for participants taking add-on lamotrigine with valproate, but without an enzyme-inducing drug, [Beran 1998](#) administered a fixed-dose of 150 mg/d lamotrigine. In contrast, the target dose for participants taking concomitant valproate in [Biton 2005](#) and [Biton 2010](#) was 200 mg/d lamotrigine, the minimum dose was 150 mg/d and the maximum was 250 mg/d. Again, this affected our ability to combine and compare the results of the three studies.

Of further significance, the approach to dosing did not reflect how lamotrigine and other antiepileptic drugs are used in practice. [Beran 1998](#) used a fixed-dose regimen, which does not reflect everyday practice; in normal clinical practice, individuals would alter their dose, dependent on their tolerability of the drug and their therapeutic response. In contrast, [Biton 2005](#) titrated doses according to



plasma levels of lamotrigine, which, again, is not routine clinical practice. Therefore, it is unclear how easily the findings would transfer to clinical practice.

On a more positive note, the two studies that contributed data to the meta-analysis did include a range of participants; for example, both adults and children were involved in both studies. A mixture of ethnicities were also recruited into the studies, most noticeably, Caucasian, Asian, and Hispanic populations. Due to our inability to complete any subgroup analyses, we were unable to determine whether the findings were generalisable to all participant demographics, or whether a participant's response to lamotrigine was dependent upon certain personal characteristics.

## Certainty of the evidence

Data from only two of the included studies contributed to the meta-analysis. Data from [Beran 1998](#) was excluded from the meta-analysis. The findings from [Beran 1998](#) are instead described in the comments column of the [Summary of findings table 1](#).

With regard to risk of bias, one of the included trials failed to describe the methodology used for random sequence generation, allocation concealment, and the blinding of participants, study personnel, and outcome assessors ([Beran 1998](#)). None of the studies provided details about whether outcome assessors were blinded. There were also issues with the reporting and handling of attrition for two of the included studies ([Beran 1998](#); [Biton 2005](#)). Both studies failed to specify the treatment allocation of a subset of participants who withdrew from treatment, and one study did not conduct intention-to-treat analyses ([Beran 1998](#)). The same study was also at risk of other bias due to the method used to calculate the baseline seizure frequency. As a result, we downgraded the evidence once for risk of bias for all seven outcomes, largely due to the concerns regarding the blinding of outcome assessors and the issue with attrition.

We also downgraded the evidence for imprecision, owing to the insufficient number of events contributing to the data analysis. Specifically, we downgraded the evidence twice for six of the outcomes because fewer than 100 events were reported per outcome. In contrast, we only downgraded the evidence for the primary outcome, 50% or greater reduction in seizure frequency, once, as more events were reported for this outcome (131 events/270 participants for the meta-analysis).

Overall, we assessed that six of the outcomes were supported by very low-certainty evidence, and one outcome was supported by low-certainty evidence. Therefore, we are uncertain to very uncertain that the findings reported are accurate of the true effect of add-on lamotrigine compared to placebo, and readers should be very cautious about how they interpret and apply the results.

## Potential biases in the review process

We conducted the review according to the standard methodological procedures expected by the Cochrane Collaboration. We therefore have no reason to suspect any major potential biases in this review.

## Agreements and disagreements with other studies or reviews

The most similar systematic review to the one conducted here was by [Bloom 2017](#). The review by [Bloom 2017](#) investigated the occurrence of adverse effects with lamotrigine monotherapy in randomised controlled trials. The authors identified 122 studies for inclusion, consisting of 18,698 participants. The incidence rate for rash was 8.3%, with 1570 participants affected in total. Although the systematic review by [Bloom 2017](#) focused on the use of lamotrigine as a monotherapy, rather than as an

add-on therapy, the evidence from the review suggests that the incidence of rash should be higher than that which has been reported by our meta-analysis.

This could be due to the different dosing regimens implemented. For example, [Beran 1998](#) used a fixed-dose method and did not describe any dose adjustments. In our review, [Beran 1998](#) reported that 27% of participants developed rash whilst receiving add-on lamotrigine, of which, two cases were serious enough for treatment to be withdrawn. No participants developed rash with add-on placebo. [Biton 2005](#) and [Biton 2010](#), however, allowed flexibility within their target doses by permitting a range of doses for each target dose. Participants were required to remain within the dose range but were allowed to adjust their dosage, as necessary, dependent on tolerability and efficacy. [Biton 2005](#) reported one mild case of generalised urticaria whilst [Biton 2010](#) reported a higher incidence rate for rash among placebo-randomised participants compared to lamotrigine-randomised participants (four versus two participants, respectively). Although [Bloom 2017](#) did not describe the dosing regimes of the included studies, we suggest that this presents one possible explanation for the difference in incidence rates.

Further to this, the systematic review by [Bloom 2017](#) also addressed the occurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis. Both conditions are classified as being severe adverse skin reactions and are considered under the category of rash. Specifically, [Bloom 2017](#) estimated that Stevens-Johnson syndrome/ toxic epidermal necrolysis affects one in 2500 participants treated with lamotrigine. Notably, none of the studies, included in our review, reported any occurrence of Stevens-Johnson syndrome or toxic epidermal necrolysis. This is easily explained by the low number of participants involved across all three studies (300 participants total) and the rarity of the event.

Although neither skin reaction was reported within our review, due to the seriousness and mortality associated with Stevens-Johnson syndrome/toxic epidermal necrolysis ([Kumar 2018](#)), it is important that this eventuality is considered when debating the clinical use of lamotrigine. Multiple studies have demonstrated that the risk of an adverse skin reaction can be minimised by the slow, gradual up-titration of lamotrigine dosage ([Ketter 2005](#); [Lorberg 2009](#)). It is, however, worth noting that people would not be effectively protected against seizures during the titration period.

## Authors' conclusions

### Implications for practice

At present, the evidence neither supports nor refutes the use of lamotrigine as an add-on for drug-resistant generalised tonic-clonic seizures.

Low-certainty evidence suggested that add-on lamotrigine may be efficacious at producing a 50% or greater reduction in primary generalised tonic-clonic seizure rate than add-on placebo. Very low-certainty evidence provided inconclusive results as to whether add-on lamotrigine affects seizure freedom rate or the incidence of adverse effects.

All outcomes in this review was rated as low to very low certainty meaning we are uncertain to very uncertain that the effects reported are accurate. Consequently, it is likely that the true effects of lamotrigine are significantly different from that reported in this review. We thus lack confidence in our findings and urge readers to interpret the results with caution.

### Implications for research

The results presented for lamotrigine's efficacy and tolerability in drug-resistant generalised tonic-clonic seizures are based on limited evidence from randomised controlled trials. The included trials varied widely in design and duration. The best studies are well-designed,



randomised, blinded, long-term, prospective trials that evaluate the efficacy and tolerability of a drug.

To more fully evaluate the role of lamotrigine, further studies are required. Such studies should address the following:

1. The minimum and maximum effective doses of lamotrigine as add-on therapy in generalised tonic-clonic seizures;
2. The long-term efficacy and safety of add-on lamotrigine in generalised onset tonic-clonic seizures;
3. How lamotrigine compares with other add-on therapies in drug-resistant generalised tonic-clonic seizures;
4. How lamotrigine interacts with standard antiepileptic drugs in people with generalised onset tonic-clonic seizures (or idiopathic generalised epilepsy);
5. Determine if people with generalised epilepsy, who have drug-resistant seizures, are physiologically or genetically different from those with readily controlled seizures;
6. Effects of lamotrigine on quality of life and cognition;
7. Economic aspects of lamotrigine therapy.

Future studies should:

1. explore multiple doses of lamotrigine and evaluate dose-response relationships;
2. introduce longer maintenance and follow-up periods;
3. incorporate active controls into their study design;
4. assess drug-interactions;
5. incorporate genetic and physiological investigations;
6. assess quality of life and cognition;
7. evaluate cost-effectiveness.

It is important to acknowledge that placebo-controlled trials in people with drug-resistant generalised tonic-clonic seizures would now be considered unethical. This is because lamotrigine is generally regarded to be beneficial, despite the findings of this current systematic review. Hence, it is more likely that any future studies would be active-controlled trials, using another antiepileptic drug as a comparator, rather than placebo-controlled.

A comparative study would still be capable of providing evidence for a therapeutic effect of lamotrigine. Findings from multiple studies using active-comparators could then be used to infer how lamotrigine would perform compared to a drug with which it has not yet been actively compared. From this viewpoint, an active-controlled trial would help the interpretation of comparative studies and could prove advantageous.

From an ethical perspective, an active-controlled trial could be of at least 12 months duration because both treatment groups would receive an active treatment. Consequently, there would be no ethical issues with regard to participants receiving a long-term inactive, placebo treatment. Trials of longer duration could measure outcomes that include seizure remissions, adverse effects with long-term exposure, and quality of life. All of these outcomes are of special significance in chronic drug-resistant epilepsy.

## Data and analyses

### Comparison 1

#### Lamotrigine versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 50% or greater reduction in primary generalized tonic-clonic seizure frequency	2	270	Risk Ratio (M-H, Fixed, 95% CI)	1.88 [1.43, 2.45]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<a href="#">1.2 Seizure freedom</a>	2	270	Risk Ratio (M-H, Fixed, 95% CI)	1.55 [0.89, 2.72]
<a href="#">1.3 Treatment withdrawal</a>	2	270	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [0.72, 1.99]
<a href="#">1.4 Adverse effects</a>	2		Risk Ratio (M-H, Fixed, 99% CI)	Subtotals only
1.4.1 Ataxia	2	270	Risk Ratio (M-H, Fixed, 99% CI)	3.05 [0.05, 199.36]
1.4.2 Dizziness	2	270	Risk Ratio (M-H, Fixed, 99% CI)	0.91 [0.29, 2.86]
1.4.3 Fatigue	2	270	Risk Ratio (M-H, Fixed, 99% CI)	1.02 [0.13, 8.14]
1.4.4 Nausea	2	270	Risk Ratio (M-H, Fixed, 99% CI)	1.60 [0.48, 5.32]
1.4.5 Somnolence	2	270	Risk Ratio (M-H, Fixed, 99% CI)	3.73 [0.36, 38.90]
1.4.6 Headache	2	270	Risk Ratio (M-H, Fixed, 99% CI)	0.75 [0.38, 1.50]
1.4.7 Vomiting	2	270	Risk Ratio (M-H, Fixed, 99% CI)	1.27 [0.39, 4.15]
1.4.8 Convulsion	2	270	Risk Ratio (M-H, Fixed, 99% CI)	0.34 [0.05, 2.13]
1.4.9 Pyrexia	2	270	Risk Ratio (M-H, Fixed, 99% CI)	0.87 [0.21, 3.52]

## What's new

Date	Event	Description
19 March 2019	New search has been performed	Searches updated 19 March 2019; included one new study ( <a href="#">Biton 2010</a> )
19 March 2019	New citation required but conclusions have not changed	Conclusions remain unchanged

## History

Protocol first published: Issue 2, 2009

Review first published: Issue 12, 2010

## Contributions of authors

Rebecca Bresnahan: assessed study eligibility, performed data extraction and risk of bias assessment. Responsible for the primary conduct and writing of the current review update.

Mariangela Panebianco: assessed study eligibility and performed data extraction and risk of bias assessment for this current review update.

Anthony G Marson: arbitrated discussions when necessary.

## Acknowledgements

We would like to thank Graham Chan for developing the search strategies and executing the electronic searches.

We would also like to thank Eugene Tjia-Leong and Kevin Leong, the previous review authors, for their contributions to the original version of this review (Tjia-Leong 2010) and to the review protocol (Tjia-Leong 2009).

## Declarations of interest

Rebecca Bresnahan: None to declare.

Mariangela Panebianco: None to declare.

Anthony G Marson: a consortium of pharmaceutical companies (GSK, Eisai, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).

## Sources of support

### Internal sources

- No sources of support supplied

### External sources

- National Institute of Health Research (NIHR), UK  
This review update was funded by the National Institute for Health Research (NIHR) [Clinically effective treatments for central nervous system disorders in the NHS, with a focus on Epilepsy and Movement Disorders (SRPG project 16/114/26)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## Differences between protocol and review

We made several changes from the review protocol and the previous version of this review during the current review update ([Tjia-Leong 2009](#); [Tjia-Leong 2010](#)).

1. We changed all references to 'refractory' epilepsy to drug-resistant, in accordance with new nomenclature ([Kwan 2010](#)).
2. We changed the definition of drug-resistant epilepsy from 'the failure to respond to one or more appropriately used AEDs', as described in the 2010 version of this review, to 'the failure to respond to adequate trials of two tolerated, appropriately chosen, and compliantly used antiepileptic drug regimens, given with the intention of achieving complete cessation of seizures'. We made this change due to the introduction of an internationally-accepted definition by the International League Against Epilepsy (ILAE ([Kwan 2010](#))).
3. We have altered the objective of the review such that it remains consistent with the objective stated in the protocol but now follows the format suggested by the Cochrane guidelines.
4. We renamed the outcomes to ensure that our terminology was consistent with other Cochrane Epilepsy reviews. Importantly, we did not change the definitions of any of the outcomes.
5. For this review update, we assessed the risk of bias, associated with the included studies, using the Cochrane 'Risk of bias' tool (see [Assessment of risk of bias in included studies](#)), rather than the Jadad validated quality scale ([Jadad 1996](#)), as stated in the review protocol.
6. We changed the measure of treatment effect from relative risk, as specified in the review protocol, to risk ratio. Relative risk is commonly misunderstood, whereas risk ratio is easier to understand and does not lead to an exaggerated sense of risk. This is an especially common issue when the event rate for the control group is unknown.
7. We specified that we used the Mantel-Haenszel statistical method to calculate the effect measure. We did not state this in either the protocol or the previous version of the review.
8. We added methods for dealing with unit of analysis issues (see [Unit of analysis issues](#)), as we did not address these in the review protocol or the previous version of the review.
9. We have changed the range for  $I^2$  value that would indicate moderate heterogeneity from 30% to 60% (defined in protocol) to 40% to 60% to prevent any uncertainty or subjectivity.
10. We specified the sensitivity analyses that would have been completed, if possible, as it we had not previously described them in either the review protocol or the previous version of the review.
11. We incorporated GRADE methodology to assess the certainty of the evidence for each outcome in this update, and developed and incorporated a 'Summary of findings' table. We did not include this in the previous version as it was not yet mandatory.

## Characteristics of studies

### Characteristics of included studies [ordered by study ID]

#### [Beran 1998](#)

##### Study characteristics

Methods	<b>Study design:</b> multicentre, randomised, double-blind, cross-over study
	<b>Country:</b> Australia

	<b>Study duration:</b> <div>1. 8-week prospective baseline;</div> <div>2. 8-week period per treatment arm;</div> <div>3. 4-week washout period, including 1-week taper.</div>	
Participants	<b>Number of randomised participants:</b> 26 <b>Type of epilepsy or seizure:</b> drug-resistant generalised epilepsy <b>Sex:</b> 11 males and 15 females <b>Age (mean):</b> 29 years (range 15 to 50) <b>Number of concomitant AEDs:</b> up to 4 other AEDs permitted <b>Number of randomised participants with tonic-clonic seizures:</b> 17 <b>Number of participants with tonic-clonic seizures included in efficacy analysis:</b> 14 <b>Monthly tonic-clonic seizure frequency at baseline (mean (range)):</b> 4.7 (1 to 24)	
Interventions	<b>Treatment arms:</b> 1 placebo, 1 lamotrigine <b>Details:</b> lamotrigine or placebo given as add-on therapy. All participants were taking valproate. Daily lamotrigine regimes were 150 mg/day for participants taking valproate and an enzyme-inducing AED versus 75 mg/day for participants taking valproate without an enzyme. Both were taken as a once daily dose. There was no information describing how placebo was administered.	
Outcomes	<div>1. 50% responder rate</div> <div>2. Withdrawal from treatment for any reason</div> <div>3. Adverse effects</div>	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: no details were provided regarding random sequence generation.
Allocation concealment (selection bias)	Unclear risk	Comment: no details were provided regarding allocation concealment.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: no details were provided regarding the blinding of participants and personnel.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: no details were provided regarding the blinding of outcome assessors.
Incomplete outcome data (attrition bias) All outcomes	High risk	<div>Quote: "Four patients withdrew before completion... These patients were included in the safety analysis but excluded from the efficacy analysis."</div> <div>Comment: the text reported the total number of treatment withdrawals (attrition), however, the text did not specify which treatment the participants were receiving when they withdrew. Furthermore, intent-to-treat analysis was not used for the efficacy analysis.</div>
Selective reporting (reporting bias)	Low risk	Comment: we were unable to attain a trial protocol, however, all outcomes defined in the methods section of the full-text publication were reported in the results section.
Other bias	Unclear risk	Quote: "Some patients were unable to record seizure numbers at occasional times during the trial, particularly those patients having frequent

	<p>absence seizures. For this reason, a seizure rate for each treatment period was calculated based on the number of days, during each treatment period, that a complete seizure record was available."</p> <p>Comment: mean monthly seizure frequency was only calculated from the days when a complete seizure record was available and could vary considerably from the true monthly seizure frequency.</p>
--	--

**Biton 2005**

Study characteristics		
Methods	<b>Study design:</b> single-centre, randomised, double-blind, parallel study <b>Country:</b> USA <b>Study duration:</b> <ol style="list-style-type: none"><li>1. Up to 2-week screening phase;</li><li>2. 8-week pre-randomisation baseline;</li><li>3. 19-week treatment period for adolescents and adult participants (aged over 12 years: 7-week dose escalation plus 12-week maintenance phase) versus a 24-week treatment period for paediatric participants (aged 2 to 12 years: 12-week dose escalation plus 12-week maintenance phase);</li><li>4. Optional entry into one year open-label continuation phase (all participants to receive lamotrigine).</li></ol>	
Participants	<b>Number of randomised participants:</b> 121 (placebo 59 participants; lamotrigine 58 participants; 4 participants did not receive either study drug) <b>Number of participants included in efficacy analysis:</b> 117 <b>Type of epilepsy or seizure:</b> primary generalised tonic-clonic seizures <b>Sex (number (%)):</b> placebo 26/59 (50%) females; lamotrigine 29/58 (44%) females <b>Age (mean <math>\pm</math> SD):</b> placebo 24.9 $\pm$ 13.8 years; lamotrigine 26.9 $\pm$ 14.6 years; age range from 2 to 55 years <b>Number of concomitant AEDs:</b> up to 2 other AEDs permitted	
Interventions	<b>Treatment arms:</b> 1 lamotrigine, 1 placebo; <b>Details:</b> lamotrigine or placebo given as add-on therapy. Lamotrigine schedule was based on age and concomitant AEDs: Participants aged 2 to 12 years: (i) taking concomitant valproate: 3 mg/kg/day target dose (200 mg/d maximum dose); (ii) taking an enzyme-inducing AED: 12 mg/kg/day target dose (400 mg/d maximum dose); (iii) taking an AED other than valproate plus an enzyme-inducing AED: 6 mg/kg/d target dose (300 mg/d maximum dose). Participants over 12 years of age: (i) taking concomitant valproate: 200 mg/d target dose; (ii) taking an enzyme-inducing AED: 400 mg/d target dose; (iii) taking an AED other than valproate plus an enzyme-inducing AED: 300 mg/d target dose.	
Outcomes	<ol style="list-style-type: none"><li>1. % change in primary generalised tonic-clonic seizure frequency monthly</li><li>2. % change in other generalised seizure types monthly</li><li>3. Median seizure counts monthly</li><li>4. Proportion of people with greater than 25% reduction in frequencies of primary generalised tonic-clonic seizures and all generalised seizures</li><li>5. Withdrawal from study for any reason</li><li>6. Adverse effects</li></ol>	
Notes	<b>Trial sponsor:</b> GlaxoSmithKline <b>Trial protocol:</b> GlaxoSmithKline Protocol LAM40097 <b>ClinicalTrials.gov identifier:</b> NCT00043901	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation	Low risk	Quote (from clinical study report): "subjects... were randomised in a 1:1 ratio according to a computer-generated randomization schedule"



(selection bias)		
Allocation concealment (selection bias)	Low risk	Quote (from clinical study report): "...those that meet entry criteria will be centrally randomised in a 1:1 ratio to receive either lamotrigine or matching placebo for lamotrigine."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote (from clinical study report): "...escalating doses of lamotrigine or matching placebo for lamotrigine."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: no details were provided regarding the blinding of outcome assessors.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "These data were analyzed for the intent-to-treat population." Comment: attrition was fully reported and intent-to-treat analysis was used. However, four randomised participants were excluded from the analysis because they did not receive at least one dose of study drug. We were not given the necessary information to incorporate these participants into our own analysis.
Selective reporting (reporting bias)	Low risk	Comment: we attained a summary protocol for the study. The results for all predefined outcomes were reported.
Other bias	Low risk	Comment: none detected

## Biton 2010

### Study characteristics

Methods	<p><b>Study design:</b> multi-centre, randomised, double-blind, parallel study</p> <p><b>Country:</b> North and South America, Europe, and Asia</p> <p><b>Study duration:</b></p> <ol style="list-style-type: none"> <li>1. Up to 2-week screening phase</li> <li>2. 8-week baseline phase</li> <li>3. 19-week treatment period (7-week double-blind dose-escalation period plus 12-week double-blind maintenance period)</li> <li>4. Optional discontinuation or entry into a 52-week continuation phase (7-week blinded transitional dosing phase plus 45-week maintenance phase)</li> </ol>
Participants	<p><b>Number of randomised participants:</b> 153 (placebo 77 participants; lamotrigine 76 participants)</p> <p><b>Number of participants included in efficacy analysis:</b> 143</p> <p><b>Type of epilepsy or seizure:</b> confident diagnosis of epilepsy with primary generalised tonic-clonic seizures</p> <p><b>Sex (number (%)):</b> placebo 38/73 (52%) females; lamotrigine 32/70 (46%) females;</p> <p><b>Age (mean <math>\pm</math> SD):</b> placebo 28.4 <math>\pm</math> 11.5 years; lamotrigine 29.4 <math>\pm</math> 12.8 years; aged 13 years and over</p> <p><b>Number of concomitant AEDs:</b> 1 to 2 AEDs permitted</p>
Interventions	<p><b>Treatment arms:</b> 1 lamotrigine, 1 placebo</p> <p><b>Details:</b> lamotrigine or placebo given as add-on therapy. Participants taking concomitant valproate: 200 mg/day; participants taking an enzyme-inducing AED with or without another AED other than valproate: 500 mg/day; participants taking an AED other than valproate and enzyme-inducing AEDs: 300 mg/day once daily</p>
Outcomes	<ol style="list-style-type: none"> <li>1. Percentage change in weekly primary generalised tonic-clonic seizure frequency</li> </ol>

	2. 50% or greater reduction in primary generalised tonic-clonic seizure frequency 3. 100% reduction in primary generalised tonic-clonic seizure frequency during the escalation and maintenance phases combined, during the escalation phase alone, and during the maintenance phase alone 4. Time taken to 50% reduction in primary generalised tonic-clonic seizure frequency 5. Percentage of participants with improvement in investigator- and participant-rated status	
Notes	<b>Trial sponsor:</b> GlaxoSmithKline <b>Trial protocol:</b> GlaxoSmithKline Protocol LAM100036 <b>ClinicalTrials.gov Identifier:</b> NCT00104416	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote (from clinical study report): "The randomization schedule will be computer-generated at GSK."
Allocation concealment (selection bias)	Low risk	Quote (from clinical study report): "Central randomization will be used in order to ensure that treatment assignment remains balanced. When a subject has met the criteria for continued study participation at the end of the baseline phase, the site will call into an IVRS (interactive voice response system) and that subject will receive the next treatment assignment as derived from the randomization schedule."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote (from clinical study report): "After randomization, all subjects will receive either LTG (lamotrigine) extended-release tablets, or matching PBO (placebo) tablets that will be provided by GSK (GlaxoSmithKline)."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: no details were provided regarding the blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Efficacy data were analyzed using the intent-to-treat population." Comment: attrition was fully reported and intent-to-treat analysis was used.
Selective reporting (reporting bias)	Low risk	Comment: we obtained a summary protocol for the study. The results for all predefined outcomes were reported.
Other bias	Low risk	Comment: none detected

[2] AED = Antiepileptic drugs

PGTC = Primary generalised tonic-clonic

## Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
<a href="#">Brzakovic 2012</a>	Not a RCT. It was also problematic that all participants were receiving lamotrigine before enrolment into the study.
<a href="#">Chung 2009</a>	Study only included participants with a diagnosis of focal epilepsy.

Study	Reason for exclusion
<a href="#">Eriksson 1998</a>	Study included participants with Lennox-Gastaut syndrome.
<a href="#">Motte 1997</a>	Study included participants with Lennox-Gastaut syndrome.
<a href="#">Sander 1990</a>	The majority of participants included in the study had focal and secondarily generalised seizures.

**RCT:** randomised controlled trial

# Appendices

## Appendix 1. CRS-web search strategy

1. (epilepax OR lamictal OR lamotrigin\*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
4. (epilep\* OR seizure\* OR convuls\*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #2 OR #3 OR #4 AND CENTRAL:TARGET
6. #1 AND #5
7. (monotherap\* NOT (adjunct\* OR "add-on" OR "add on" OR adjuvant\* OR combination\* OR polytherap\*)):TI AND CENTRAL:TARGET
8. #6 NOT #7
9. >24/02/2014:CRSCREATED AND CENTRAL:TARGET
10. #8 AND #9

## Appendix 2. MEDLINE search strategy

This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials ([Lefebvre 2011](#)).

1. (epilepax OR lamictal OR lamotrigin\$).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep\$ or seizure\$ or convuls\$).tw.
5. 2 or 3 or 4
6. exp \*Pre-Eclampsia/ or exp \*Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt.  
or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap\$ not (adjunct\$ or "add-on" or "add on" or adjuvant\$ or combination\$ or polytherap\$)).ti.

16. 14 not 15
17. limit 16 to ed=20100601-20190319
18. 16 not (1\$ or 2\$).ed.
19. 18 and 201\$.dt.
20. 17 or 19
21. remove duplicates from 20

## Appendix 3. ICTRP search strategy

Condition: epilepsy

Intervention: epilepax OR lamictal OR lamotrigine

Recruitment status: all

Date of registration between 24/02/2014 and 19/03/2019

## References

### References to studies included in this review

#### Beran 1998 {published data only}

[2630375](#)

Beran RG , Berkovic SF , Dunagan FM , Vajda FJ , Danta G , Black AB , et al.  
Double-blind placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. *Epilepsia* 1998;39(12):1329-33. [2630376](#)

#### Biton 2005 {published data only}

[2630377](#)

- \* Biton V , Sackellares JC , Vuong A , Hammer AE , Barrett PS , Messenheimer JA . Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. *Neurology* 2005;65:1737-43. [13957167](#)
- LAM40097. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic Seizures (Study GI267119). [www.gsk-studyregister.com/study?uniqueStudyId=LAM40097](http://www.gsk-studyregister.com/study?uniqueStudyId=LAM40097) (accessed 20 May 2019) . [13957168](#)
- NCT00043901. Treatment of primary generalized tonic-clonic seizures with an investigational new drug [A multi-center, double-blind, randomized, placebo-controlled, parallel-group evaluation of lamotrigine adjunctive therapy in subjects with primary generalized tonic-clonic seizures]. <https://clinicaltrials.gov/ct2/show/NCT00043901> (first received 16 August 2002) . [13957169](#)
- Tabbaa M , Kerls SP , Hammer AE , Vuong A , Messenheimer JA . Evaluation of lamotrigine adjunctive therapy for primary generalized tonic-clonic seizures in patients with a history of absence epilepsy. *Epilepsia* 2006;47(S4):47. [13957170](#)
- Trevathan E , Kerls SP , Hammer AE , Vuong A , Messenheimer JA . Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. *Paediatrics* 2006;118(2):371-8. [2630379](#)

#### Biton 2010 {published data only}

[13957171](#)

- \* Biton V , Di Memmo J , Shukla R , Lee YY , Poverennova I , Demchenko V , et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. *Epilepsy & Behavior* 2010;19(3):352-8. [13957172](#)
- EUCTR2004-004343-21. A multicenter, double-blind, randomized, parallel-group evaluation of LAMICTAL extended-release adjunctive therapy in subjects with primary generalized tonic-clonic seizures. [www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004343-21](http://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004343-21) (first received 12 January 2005) . [13957173](#)
- LAM100036. A multicenter, double-blind, randomized, parallel-group evaluation of LAMICTAL extended-release adjunctive therapy in subjects with primary generalized tonic-clonic seizures. [www.gsk-studyregister.com/study?uniqueStudyId=LAM100036](http://www.gsk-studyregister.com/study?uniqueStudyId=LAM100036) (accessed 30 April 2019) . [13957174](#)
- NCT00104416. A multicenter, double-blind, randomized, parallel-group evaluation of LAMICTAL extended-release adjunctive therapy in patients with primary generalized tonic-clonic seizures. [clinicaltrials.gov/ct2/show/study/NCT00104416](http://clinicaltrials.gov/ct2/show/study/NCT00104416) (first received 18 May 2010) . [13957175](#)

## References to studies excluded from this review

### Brzakovic 2012 {published data only}

[13957176](#)

Brzakovic BB , Vezmar Kovacevic SD , Vucicevic KM , Miljkovic BR , Martinovic ZJ , Pokrajac MV , et al. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. *Journal of Clinical Pharmacy and Therapeutics* 2012;37(6):693-7. [13957177](#)

### Chung 2009 {published data only}

[13957178](#)

Chung SS , Kerls S , Hammer A , Kustra R . Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy. *Neurology International* 2009;1(1):e6. [13957179](#)

### Eriksson 1998 {published data only}

[2630380](#)

Eriksson AS , Nergardh A , Hoppu K . The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. *Epilepsia* 1998;39(5):495-501. [2630381](#)

### Motte 1997 {published data only}

[13957180](#)

Motte J , Trevathan E , Arvidsson JFV , Barrera MN , Mullens EL , Manasco P . Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. *New England Journal of Medicine* 1997;337:1807-12. [13957181](#)

### Sander 1990 {published data only}

[2630384](#)

Sander JWA , Patsalos PN , Oxley JR , Hamilton MJ , Yuen WC . A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. *Epilepsy Research* 1990;6:221-6. [2630385](#)

## Additional references

### Bancaud 1989

Bancaud J , Henriksen O , Rubio-Donnadieu F , Seino M , Dreifuss FE , Kiffin Penry JK , International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. *Epilepsia* 1989;30:389-99.

### Besag 1998

Besag FM , Berry DJ , Pool F , Newbery JE , Subel B . Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? *Epilepsia* 1998;39(2):183-7. [PMID: [9577998](#)]

### Bloom 2017

Bloom R , Amber KT . Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. *Anais Brasileiros De Dermatologia* 2017;92(1):139-41.

### Brigo 2019

Brigo F , Igwe SC , Lattanzi S . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. *Cochrane Database of Systematic Reviews* 2019, Issue 2. [DOI: [10.1002/14651858.CD003032.pub4](#)]

### Cockerell 1995

Cockerell OC , Johnson AL , Sander JW , Hart YM , Shorvon SD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. *Lancet* 1995;346(8968):140-4.

### Deng 2013

Deng Y , Wang M , Jiang L , Ma C , Xi Z , Li X , et al. A comparison of extracellular excitatory amino acids release inhibition of acute lamotrigine and topiramate treatment in the hippocampus of PTZ-kindled epileptic rats. *Journal of Biomedical Nanotechnology* 2013;9(6):1123-8. [PMID: [23858978](#)]

### Fiest 2017

Fiest KM , Sauro KM , Wiebe S , Patten SB , Kwon CS , Dykeman J , et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. *Neurology* 2017;88(3):296-303. [PMID: [27986877](#)]

### GRADEpro GDT [Computer program]

GRADEpro GDT. Version accessed 9 May 2019. Hamilton (ON): McMaster University (developed by Evidence Prime) .Available at [gradepr.org](#).

### Hajian-Tillaki 2011

Hajian-Tilaki K . Sample size estimation in epidemiologic studies. *Caspian Journal of Internal Medicine* 2011;2(4):289-98.

### Hancock 2013

Hancock EC , Cross HJ . Treatment of Lennox-Gastaut syndrome. *Cochrane*



Database of Systematic Reviews 2013, Issue 2. [DOI:  
[10.1002/14651858.CD003277.pub3](https://doi.org/10.1002/14651858.CD003277.pub3)]

## Higgins 2011

Higgins JPT , Green S , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org) .

## Higgins 2017

Higgins JPT , Altman DG , Sterne JAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook) .

## Jadad 1996

Jadad AR , Moore RA , Carroll D , Jenkinson C , Reynolds DJ , Gavaghan DJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Controlled Clinical Trials* 1996;17(1):1-12.

## Ketter 2005

Ketter TA , Wang PW , Chandler RA , Alarcon AM , Becker OV , Nowakowska C , et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. *The Journal of Clinical Psychiatry* 2005;66(5):642-5. [PMID: [15889953](https://pubmed.ncbi.nlm.nih.gov/15889953/)]

## Kumar 2018

Kumar R , Das A , Das S . Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines! *Indian Journal of Dermatology* 2018;63(2):117-24. [PMID: [29692452](https://pubmed.ncbi.nlm.nih.gov/29692452/)]

## Kwan 2010

Kwan P , Arzimanoglou A , Berg AT , Brodie MJ , Allen Hauser W , Mathern G , et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010;51(6):1069-77. [PMID: [19889013](https://pubmed.ncbi.nlm.nih.gov/19889013/)]

## Leach 1995

Leach LJ , Lees G , Riddall DR . Lamotrigine. In: Levy RH , editors(s). *Mechanisms of Action in Antiepileptic Drugs*. 4th edition. New York: Raven Press, 1995 .

## Lefebvre 2011

Lefebvre C , Manheimer E , Glanville J . Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org) .

## Lorberg 2009

Lorberg B , Youssef NA , Bhagwagar Z . Lamotrigine-associated rash: to rechallenge or not to rechallenge? *The International Journal of Neuropsychopharmacology* 2009;12(2):257-65. [PMID: [18845017](https://pubmed.ncbi.nlm.nih.gov/18845017/)]

## Marson 2007

Marson AG , Al-Kharusi AM , Alwaidh M , Appleton R , Baker GA , Chadwick DW , et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. *Lancet* 2007;369:1016-26.

## Ramaratnam 2016

Ramaratnam S , Panebianco M , Marson AG . Lamotrigine add-on for drug-resistant partial epilepsy. *Cochrane Database of Systematic Reviews* 2016, Issue 6. [DOI: [10.1002/14651858.CD001909.pub2](https://doi.org/10.1002/14651858.CD001909.pub2)]

## Review Manager 2014 [Computer program]

Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

## Rowland 2006

Rowland A , Elliot DJ , Williams JA , Mackenzie PI , Dickinson RG , Miners JO . In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. *Drug Metabolism and Disposition* 2006;34(6):1055-62. [PMID: [16565174](https://pubmed.ncbi.nlm.nih.gov/16565174/)]

## Schünemann 2013

Schünemann H , Brożek J , Guyatt G , Oxman A , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from [gdt.guidelinedevelopment.org/app/handbook/handbook.html](http://gdt.guidelinedevelopment.org/app/handbook/handbook.html) .

## Weintraub 2005

Weintraub D , Buchsbaum R , Resor SR Jr, Hirsch LJ . Effect of antiepileptic drug co-medication on lamotrigine clearance. *Archives of Neurology* 2005;62(9):1432-6.

## WHO 2019

World Health Organization (WHO). Epilepsy. [www.who.int/news-room/fact-sheets/detail/epilepsy](http://www.who.int/news-room/fact-sheets/detail/epilepsy) (accessed 17 May 2019) .

## References to other published versions of this review

### Tjia-Leong 2009

Tjia-Leong E , Leong K , Marson A . Lamotrigine add-on for refractory generalized tonic-clonic seizures. *Cochrane Database of Systematic Reviews* 2009, Issue 2. [DOI: [10.1002/14651858.CD007783](https://doi.org/10.1002/14651858.CD007783)]

### Tjia-Leong 2010

Tjia-Leong E , Leong K , Marson AG . Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. *Cochrane Database of Systematic Reviews* 2010, Issue 12. [DOI: [10.1002/14651858.CD007783.pub2](https://doi.org/10.1002/14651858.CD007783.pub2)]

# Figures and tables

## Additional tables


Table 1

Quality of life



Treatment group	Overall score for QOLIE-31P			Change in overall score for QOLIE-31P from baseline to week 19 of treatment	
	Time point	Number of participants analysed	Mean (SD)	Number of participants analysed	Least squares mean (SE)
Placebo	Baseline	19	61.1 (17.1)	18	-6.5 (4.0)
	End of study	20	66.4 (14.8)		
Lamotrigine	Baseline	17	54.3 (9.9)	15	-8.5 (4.4)
	End of study	15	65.6 (20.4)		

**SD:** standard deviation; **SE:** standard error; **QOLIE-31P:** Quality of Life in Epilepsy Inventory-31 Patient-weighted.




**Figure 2**

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies




**Analysis 1.1**

Comparison 1: Lamotrigine versus placebo, Outcome 1: 50% or greater reduction in primary generalized tonic-clonic seizure frequency




### Analysis 1.2

#### Comparison 1: Lamotrigine versus placebo, Outcome 2: Seizure freedom




### Analysis 1.3

#### Comparison 1: Lamotrigine versus placebo, Outcome 3: Treatment withdrawal



### Analysis 1.4

#### Comparison 1: Lamotrigine versus placebo, Outcome 4: Adverse effects





Forest plot showing the effect of lamotrigine add-on therapy on the risk of adverse events.

**1.4.4 Nausea**

Biton 2005	6	58	3	59	42.8%	2.03 [0.35 , 11.80]
Biton 2010	5	76	4	77	57.2%	1.27 [0.24 , 6.77]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>1.60 [0.48 , 5.32]</b>
Total events:	11		7			
Heterogeneity: Chi <sup>2</sup> = 0.25, df = 1 (P = 0.62); I <sup>2</sup> = 0%						
Test for overall effect: Z = 1.00 (P = 0.32)						

**1.4.5 Somnolence**

Biton 2005	4	58	1	59	66.6%	4.07 [0.24 , 69.66]
Biton 2010	1	76	0	77	33.4%	3.04 [0.05 , 199.82]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>3.73 [0.36 , 38.90]</b>
Total events:	5		1			
Heterogeneity: Chi <sup>2</sup> = 0.02, df = 1 (P = 0.88); I <sup>2</sup> = 0%						
Test for overall effect: Z = 1.44 (P = 0.15)						

**1.4.6 Headache**

Biton 2005	10	58	15	59	55.5%	0.68 [0.27 , 1.73]
Biton 2010	10	76	12	77	44.5%	0.84 [0.30 , 2.34]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>0.75 [0.38 , 1.50]</b>
Total events:	20		27			
Heterogeneity: Chi <sup>2</sup> = 0.17, df = 1 (P = 0.68); I <sup>2</sup> = 0%						
Test for overall effect: Z = 1.06 (P = 0.29)						

**1.4.7 Vomiting**

Biton 2005	3	58	5	59	62.5%	0.61 [0.10 , 3.77]
Biton 2010	7	76	3	77	37.5%	2.36 [0.42 , 13.31]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>1.27 [0.39 , 4.15]</b>
Total events:	10		8			
Heterogeneity: Chi <sup>2</sup> = 1.93, df = 1 (P = 0.16); I <sup>2</sup> = 48%						
Test for overall effect: Z = 0.52 (P = 0.60)						

**1.4.8 Convulsion**

Biton 2005	2	58	6	59	80.0%	0.34 [0.04 , 2.63]
Biton 2010	0	76	1	77	20.0%	0.34 [0.01 , 22.20]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>0.34 [0.05 , 2.13]</b>
Total events:	2		7			
Heterogeneity: Chi <sup>2</sup> = 0.00, df = 1 (P = 1.00); I <sup>2</sup> = 0%						
Test for overall effect: Z = 1.51 (P = 0.13)						

**1.4.9 Pyrexia**

Biton 2005	1	58	3	59	42.8%	0.34 [0.02 , 6.39]
Biton 2010	5	76	4	77	57.2%	1.27 [0.24 , 6.77]
<b>Subtotal (99% CI)</b>		<b>134</b>		<b>136</b>	<b>100.0%</b>	<b>0.87 [0.21 , 3.52]</b>
Total events:	6		7			
Heterogeneity: Chi <sup>2</sup> = 1.02, df = 1 (P = 0.31); I <sup>2</sup> = 2%						
Test for overall effect: Z = 0.26 (P = 0.80)						

0.005 0.1 1 10 200  
Favours lamotrigine Favours placebo